促性腺激素释放激素激动剂对大鼠卵巢腺癌细胞系的体内外作用
Effects of a gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo.
作者信息
Maruuchi T, Sugiyama T, Kataoka A, Nishida T, Yakushiji M
机构信息
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka.
出版信息
Jpn J Cancer Res. 1998 Sep;89(9):977-83. doi: 10.1111/j.1349-7006.1998.tb00657.x.
To evaluate the biologic effects of the gonadotropin-releasing hormone (GnRH) agonist buserelin on rat ovarian adenocarcinoma cells in vivo and in vitro, female Wistar rats with primary ovarian adenocarcinoma induced by 7, 12-dimethylbenz(a)anthracene (DMBA) and the DMBA-OC-1 cell line established from a DMBA-induced rat tumor were used in this study. In vivo, daily administration of buserelin significantly suppressed the release of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and progesterone as compared with controls. Buserelin did not inhibit the growth of DMBA-induced tumors. However, histopathologically, there was increased central necrosis and a decrease in the number of neoplastic cells, with proliferation of connective tissue, in the group treated with buserelin. In vitro, FSH-induced proliferation of DMBA-OC-1 cells was suppressed by buserelin. Thus, this basic experimental study supports the potential use of a GnRH agonist to suppress the growth of ovarian cancer.
为了评估促性腺激素释放激素（GnRH）激动剂布舍瑞林在体内和体外对大鼠卵巢腺癌细胞的生物学效应，本研究使用了经7,12-二甲基苯并(a)蒽（DMBA）诱导产生原发性卵巢腺癌的雌性Wistar大鼠，以及从DMBA诱导的大鼠肿瘤中建立的DMBA-OC-1细胞系。在体内，与对照组相比，每日给予布舍瑞林可显著抑制促卵泡激素（FSH）、促黄体生成素（LH）和孕酮的释放。布舍瑞林并未抑制DMBA诱导的肿瘤生长。然而，在组织病理学上，布舍瑞林治疗组的肿瘤中央坏死增加，肿瘤细胞数量减少，结缔组织增生。在体外，布舍瑞林可抑制FSH诱导的DMBA-OC-1细胞增殖。因此，这项基础实验研究支持了GnRH激动剂在抑制卵巢癌生长方面的潜在应用。
Zotero 插件